<DOC>
	<DOC>NCT00370370</DOC>
	<brief_summary>To compare the efficacy and safety results of intravitreal bevacizumab alone with bevacizumab + triamcinolone acetonide in neovascular AMD.</brief_summary>
	<brief_title>Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Cases of active neovascular AMD with visual acuity of 20/400 20/40 History of glaucoma or ocular hypertension Disciform scar</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Bevacizumab,</keyword>
	<keyword>Triamcinolone</keyword>
	<keyword>Age-related macular degeneration</keyword>
	<keyword>Choroidal neovascular membrane</keyword>
</DOC>